TIDMHIK
RNS Number : 1111Y
Hikma Pharmaceuticals Plc
12 May 2016
Hikma Pharmaceuticals PLC
Voting Results of 2016 Annual General Meeting
LONDON, 12 May 2016 - Hikma Pharmaceuticals PLC (the "Company")
announces its Annual General Meeting ("AGM"), held at The Westbury,
Bond Street, Mayfair, London W1S 2YF on 12 May 2016 commenced at
11:00 am today. All resolutions were duly passed by shareholders by
way of a poll. Resolutions 1 to 16 were passed as ordinary
resolutions and Resolutions 17 to 19 were passed as special
resolutions.
As previously announced, Mr. Breffni Byrne retired from the
Board at the close of the AGM.
Copies of the resolutions dealing with special business passed
at the AGM have been submitted to the UK Listing Authority for
publication through the Listing Authority's Document Viewing
Facility.
The total number of votes cast on the poll for each resolution
(the full text of the resolutions is detailed in the notice of the
AGM dated 7 April 2016). is set out below. The number of Ordinary
Shares in issue on 12 May 2016 was 239,385,501.
Resolution Votes % Votes % Votes
For Against Withheld
--- ------------------------------- ------------ -------- ----------- ------- ----------
To receive the
2015 report and
1 accounts 201,043,426 99.83% 347,462 0.17% 197,375
--- ------------------------------- ------------ -------- ----------- ------- ----------
To approve a final
dividend of 21
2 cents per share 201,588,263 100.00% 0 0.00% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Appoint PricewaterhouseCoopers
3 LLP as auditors 198,964,787 98.70% 2,623,476 1.30% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Authorise the
Audit Committee
to set the remuneration
4 of the auditors 194,789,399 96.63% 6,798,864 3.37% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Appoint Jochen
5 Gann 199,061,688 98.75% 2,526,551 1.25% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
6 Appoint John Castellani 200,675,819 99.55% 912,421 0.45% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Reappointment
7 of Said Darwazah 196,614,743 97.69% 4,641,117 2.31% 332,378
--- ------------------------------- ------------ -------- ----------- ------- ----------
Reappointment
8 of Mazen Darwazah 197,410,765 97.93% 4,177,474 2.07% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Reappointment
9 of Robert Pickering 199,988,353 99.21% 1,599,886 0.79% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Reappointment
10 of Ali Al Husry 199,090,927 98.76% 2,497,312 1.24% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Reappointment
11 of Michael Ashton 196,521,848 98.45% 3,095,916 1.55% 1,970,475
--- ------------------------------- ------------ -------- ----------- ------- ----------
Reappointment
12 of Ronald Goode 198,210,008 99.05% 1,901,133 0.95% 1,477,098
--- ------------------------------- ------------ -------- ----------- ------- ----------
Reappointment
13 of Patrick Butler 200,562,012 99.49% 1,026,227 0.51% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Reappointment
14 of Dr Pamela Kirby 199,880,568 99.15% 1,707,671 0.85% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Approve the 2015
15 remuneration implementation 173,423,087 88.97% 21,510,812 11.03% 6,654,338
--- ------------------------------- ------------ -------- ----------- ------- ----------
Authorise the
directors to allot
16 shares 176,261,935 87.65% 24,841,433 12.35% 484,894
--- ------------------------------- ------------ -------- ----------- ------- ----------
Disapply pre-emption
17 rights 179,904,929 90.65% 18,558,726 9.35% 3,124,607
--- ------------------------------- ------------ -------- ----------- ------- ----------
Authorise the
company to buy
18 back shares 200,673,199 99.55% 915,063 0.45% 0
--- ------------------------------- ------------ -------- ----------- ------- ----------
Authorise the
company to call
general meetings
19 on 14 days' notice 185,097,715 91.88% 16,365,074 8.12% 125,473
--- ------------------------------- ------------ -------- ----------- ------- ----------
Declaration of final dividend
The dividend of 21 cents per share will be paid on 19 May 2016
to shareholders on the register on 8 April 2016. Shareholders who
are not resident in Jordan have been given the option of receiving
their dividend in Pounds Sterling. The exchange rate in respect of
this dividend will be $1.4510 to GBP1. The exchange rate for
Jordanian Dinar is fixed to the US Dollar at 1JD to $1.4104.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
VP for Investor Relations and
Strategy +44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2015, Hikma achieved
revenues of $1,440 million and profit attributable to shareholders
of $252 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSFFFLEFMSEFI
(END) Dow Jones Newswires
May 12, 2016 10:14 ET (14:14 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
